Artia Global Partners LP
An institutional investment manager in MIAMI, FL. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1937964.
- Reported value$541.9m
- Positions48
Holdings: 48 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Abivax SAABVX | SPONSORED ADS | 00370M103 | 68.8 | 12.7% | 516,447 | Reduced−84,300 | |
| Insmed IncINSM | COM PAR $.01 | 457669307 | 62.8 | 11.6% | 589,052 | Reduced−39,660 | |
| Trevi Therapeutics IncTRVI | COM | 89532M101 | 41.2 | 7.6% | 2,210,852 | Added+197,250 | |
| Brightspring Health SVCS IncBTSG | COM | 10950A106 | 36.1 | 6.7% | 517,315 | Added+463,515 | |
| Revolution Medicines IncRVMD | COM | 76155X100 | 34.7 | 6.4% | 185,390 | Added+60,400 | |
| Argenx SEARGX | SPONSORED ADR | 04016X101 | 27.6 | 5.1% | 29,739 | Unchanged | |
| Alkermes plc | SHS | G01767105 | 23.5 | 4.3% | 448,964 | New+448,964 | |
| Travere Therapeutics IncTVTX | COM | 89422G107 | 19.3 | 3.6% | 339,033 | Added+268,333 | |
| Astrazeneca plc | ORD | G0593M107 | 18.7 | 3.4% | 98,376 | Added+3,000 | |
| Newamsterdam Pharma Company | ORDINARY SHARES | N62509109 | 17.1 | 3.2% | 503,936 | Unchanged | |
| Dianthus Therapeutics IncDNTH | COM | 252828108 | 15.9 | 2.9% | 162,990 | Unchanged | |
| SPDR Series Trust | ST STR SP BIOT | 78464A870 | 15.8 | 2.9% | 100,000 | Put | New+100,000 |
| Quest Diagnostics IncDGX | COM | 74834L100 | 13.8 | 2.5% | 65,122 | Added+24,305 | |
| Ionis Pharmaceuticals IncIONS | COM | 462222100 | 11.4 | 2.1% | 144,376 | Unchanged | |
| Eyepoint IncEYPT | COM NEW | 30233G209 | 11.0 | 2.0% | 767,098 | Unchanged | |
| Alumis IncALMS | COM | 022307102 | 7.8 | 1.4% | 278,546 | Reduced−46,500 | |
| Viking Therapeutics IncVKTX | COM | 92686J106 | 7.1 | 1.3% | 180,731 | Unchanged | |
| Celcuity IncCELC | COM | 15102K100 | 6.2 | 1.1% | 59,316 | Added+43,740 | |
| Cytokinetics IncCYTK | COM NEW | 23282W605 | 6.0 | 1.1% | 70,700 | Added+54,400 | |
| Merck & Co IncMRK | COM | 58933Y105 | 6.0 | 1.1% | 46,700 | Unchanged | |
| Rapport Therapeutics IncRAPP | COM | 75383L102 | 5.8 | 1.1% | 138,508 | Unchanged | |
| Johnson & JohnsonJNJ | COM | 478160104 | 5.7 | 1.1% | 22,600 | Unchanged | |
| Guardant Health IncGH | COM | 40131M109 | 5.7 | 1.1% | 38,100 | New+38,100 | |
| Absci CorporationABSI | COM | 00091E109 | 5.4 | 1.0% | 464,444 | New+464,444 | |
| Scholar Rock HLDG CorpSRRK | COM | 80706P103 | 5.3 | 1.0% | 96,285 | Unchanged | |
| Sionna Therapeutics IncSION | COM | 829401108 | 5.3 | 1.0% | 119,741 | Unchanged | |
| Ascendis Pharma A/S | ORD SHS | K08588103 | 4.7 | 0.9% | 17,740 | New+17,740 | |
| Roivant Sciences Ltd | SHS | G76279101 | 4.6 | 0.8% | 129,800 | Unchanged | |
| Palisade Bio IncPALI | COM | 696389402 | 4.2 | 0.8% | 1,992,367 | Unchanged | |
| Edgewise Therapeutics IncEWTX | COM | 28036F105 | 4.0 | 0.7% | 98,800 | Added+33,300 | |
| Biogen IncBIIB | COM | 09062X103 | 4.0 | 0.7% | 18,437 | Unchanged | |
| Xenon Pharmaceuticals IncXENE | COM | 98420N105 | 3.9 | 0.7% | 65,000 | Unchanged | |
| Belite Bio IncBLTE | SPONSORED ADS | 07782B104 | 3.8 | 0.7% | 24,989 | Unchanged | |
| Mineralys Therapeutics IncMLYS | COM | 603170101 | 3.7 | 0.7% | 137,800 | Unchanged | |
| Prokidney CorpPROK | SHS CL A | 74291D104 | 3.7 | 0.7% | 1,806,939 | Unchanged | |
| Enliven Therapeutics IncELVN | COM | 29337E102 | 3.7 | 0.7% | 72,100 | Added+51,200 | |
| Oruka Therapeutics IncORKA | COM | 687604108 | 3.2 | 0.6% | 33,400 | New+33,400 | |
| Protagonist Therapeutics IncPTGX | COM | 74366E102 | 2.8 | 0.5% | 22,951 | Added+20 | |
| United Therapeutics Corp DelUTHR | COM | 91307C102 | 2.7 | 0.5% | 5,000 | Unchanged | |
| Bright Minds Biosciences IncDRUG | COM NEW | 10919W405 | 2.7 | 0.5% | 38,407 | Unchanged | |
| Kiniksa Pharmaceuticals International | ORD SHS CL A | G52694109 | 1.9 | 0.3% | 29,200 | Unchanged | |
| Compass Therapeutics IncCMPX | COM | 20454B104 | 0.8 | 0.2% | 383,200 | New+383,200 | |
| Praxis Precision Medicines IPRAX | COM NEW | 74006W207 | 0.8 | 0.2% | 2,500 | Unchanged | |
| Kodiak Sciences IncKOD | COM | 50015M109 | 0.7 | 0.1% | 17,019 | Unchanged | |
| Tenax Therapeutics IncTENX | COM NEW | 88032L605 | 0.6 | 0.1% | 42,080 | Unchanged | |
| Nuvalent Inc | COM | 670703107 | 0.6 | 0.1% | 4,900 | Unchanged | |
| Pepgen IncPEPG | COM | 713317105 | 0.4 | <0.1% | 205,324 | Unchanged | |
| Spyre Therapeutics IncSYRE | COM NEW | 00773J202 | 0.4 | <0.1% | 4,000 | New+4,000 |
Sold out: 10 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Abbvie IncABBV | COM | 00287Y109 | 0.0 | 0.0% | 0 | Sold out−14,500 | |
| Apogee Therapeutics Inc | COM | 03770N101 | 0.0 | 0.0% | 0 | Sold out−5,886 | |
| Ascendis Pharma A/S | SPONSORED ADR | 04351P101 | 0.0 | 0.0% | 0 | Sold out−17,740 | |
| Avalo Therapeutics IncAVTX | COM NEW | 05338F306 | 0.0 | 0.0% | 0 | Sold out−28,970 | |
| Bridgebio Pharma IncBBIO | COM | 10806X102 | 0.0 | 0.0% | 0 | Sold out−20,400 | |
| ELI Lilly & CoLLY | COM | 532457108 | 0.0 | 0.0% | 0 | Sold out−38,220 | |
| Insmed IncINSM | COM PAR $.01 | 457669307 | 0.0 | 0.0% | 0 | Put | Sold out−279,700 |
| Moderna IncMRNA | COM | 60770K107 | 0.0 | 0.0% | 0 | Call | Sold out−200,000 |
| Soleno Therapeutics Inc | COM | 834203309 | 0.0 | 0.0% | 0 | Sold out−68,490 | |
| Terns Pharmaceuticals Inc | COM | 880881107 | 0.0 | 0.0% | 0 | Sold out−104,800 |
Source: SEC EDGAR, Form 13F-HR, accession 0001937964-26-000008 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.